Ladenburg thalmann to host scientific showcase december 18, 2024 about rare disease clinical development efforts for jaguar health's crofelemer

Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (iit) and two phase 2 studies - for the rare disease indications of microvillus inclusion disease (mvid) and/or short bowel syndrome with intestinal failure (sbs-if) in the us, eu, and/or middle east/north africa regions; availability of iit proof-of-concept results potentially in q2 2025 virtual event 11:00 am to 12:00 pm eastern registration open now for financial and business community; click here to register massimo radaelli, phd, ceo of the rare disease-focused jaguar family company napo therapeutics and president of jaguar international, named ‘ best ceo biopharmaceuticals of the year ' san francisco, ca / accesswire / december 13, 2024 / jaguar health, inc. (nasdaq:jagx) (jaguar) today announced that ladenburg thalmann is hosting a scientific showcase webinar on wednesday, december 18, 2024 from 11:00 a.m. to 12:00 p.m.
JAGX Ratings Summary
JAGX Quant Ranking